alpha-halogenoacrylic derivatives of antitumor agents.

Abstract

In this review article we have reported a series of hybrid compounds characterized by the presence of a alpha-halogenocryloyl alkylating moiety of low chemical reactivity, linked to known antitumor agents or their active moieties. Among them, brostallicin (PNU-166196), was selected for clinical development and is now undergoing Phase II studies in patients with advanced or metastatic soft tissue sarcoma.

• Authors: Romeo Romagnoli, Pier Giovanni Baraldi, Olga Cruz-Lopez, Carlota Lopez-Cara, Delia Preti
• Journal: Mini reviews in medicinal chemistry (Mini Rev Med Chem) Vol. 9 Issue 1 Pg. 81-94 (Jan 2009) ISSN: 1389-5575 [Print] Netherlands
• PMID: 19149662 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents, Alkylating
• Distamycins
• Guanidines
• Pyrroles
• Pyrroloiminoquinones
• stallimycin
• brostallicin

Topics

• Animals
• Antineoplastic Agents, Alkylating (chemistry, pharmacology)
• Cell Line, Tumor
• Distamycins (chemistry, pharmacology)
• Guanidines (chemistry, therapeutic use)
• Humans
• Mice
• Pyrroles (chemistry, therapeutic use)
• Pyrroloiminoquinones (chemistry, pharmacology)